Vivek Subbiah: Fragmentation in medicine harms patients and hinders research

Vivek Subbiah shared on LinkedIn:

“Just published in Nature Medicine:

Fragmentation in medicine harms patients and hinders research– World view

Author: Vivek Subbiah

Transforming the fragmented silos of medicine into a wheel of collaboration holds the key to tackling complex health challenges for generations to come.”

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.

Find other posts featuring Vivek Subbiah on OncoDaily.